This timeline offers a historical view of significant U.S. federal policies and events spanning the early 1800s to today that have influenced present-day health disparities....
Moultrie explains that “people from marginalized populations must be fully welcome and treated equitably, sharing the same experience as earlier participants in all these discussions. This includes having updates on earlier conversations to enable full participation in current discussions....
Patients who find themselves at the intersection of rare diseases and marginalized populations are at critical risk, and our healthcare system is ill-equipped to support them....
Recent news highlighted the escalating concerns with the adoption of new artificial intelligence (AI) tools aimed at streamlining operations for tasks traditionally seen as expensive and complex, like recruitment processes....
There are long-standing health disparities for communities of color and LGBTQIA+ in Wisconsin and Illinois. Many causes exist for these disparities, such as inadequate access to health care, environmental factors, lack of financial resources, historically inequitable approaches to treatment, and racism....
A panel at the 2024 SCOPE Summit shared their experiences of setting up and running clinical trials that are more inclusive of the LGBTQIA+ community....
2024 is a critical year for professionals throughout the clinical research enterprise to build on the momentum gained in 2023 for improving diversity, equity, and inclusion (DEI) among clinical trials participants and other stakeholders. ...
The longstanding problem of pulse oximeters providing less-accurate readings for people with dark skin tones is getting another look from a panel of experts for the US Food and Drug Administration....
Recently, a team of medical researchers have been using artificial intelligence to uncover the experiences and unmet needs of sickle cell patients....
The US Food and Drug Administration (FDA) is outlining a standardized approach for collecting and reporting on race and ethnicity data in clinical trials and studies in a new draft guidance document....
